Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Investec shares dip as full-year guidance disappoints

(Sharecast News) - Shares in Investec dropped on Thursday after the international bank and wealth manager underwhelmed with its guidance for the year ending 31 March, with adjusted profits expected to rise by 5-12%. Pre-provision adjusted operating profit should be between £1.01bn and £1.08bn, up from £964m the year before. This was helped by the cost-to-income ratio being below the 53.8% reported in the prior year, benefitting from revenue growing ahead of costs.

Revenue growth was said to be supported by continued client acquisition, strong net inflows in discretionary and annuity funds under management and higher average advances.

However, basic earnings per share guidance was just 67.2p-73.5p, representing a 30-36% drop on last year's results. Invetec said: "The prior year was positively impacted by the significant net gain from the implementation of the UK Wealth & Investment combination with Rathbones which was partially offset by the effects of Burstone's deconsolidation; and the amortisation of intangible assets associated with the Rathbones combination in the current period."

Group adjusted operating profit before tax should be between £888m and £956m, representing mild growth from the previous year (£885m).

The South African business is expected to post 5% adjusted profit growth in rands to £429m, though the guidance range for the UK business points to earnings growth of -4% to +4%.

Shares were down 4.5% at 493.28p by 0842 GMT.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.